Move to the content areaUserLogin
 
change language:

メニュー/MENU

TOP　Page
○○学科

▶大学ホームページに戻る

▶Return to University HOME

 

researchmapからのお知らせ

絵文字:NEW研究者のみなさまへ
 

研究者検索

Researcher Search Results >> Hiroyuki Suzuki
 

last update:

edit

Hiroyuki Suzuki

 
Avatar
NameHiroyuki Suzuki
URL
AffiliationChiba University
SectionGraduate School of Pharmaceutical Sciences
Job title助教
Degree(BLANK)(Chiba University)
Research funding number00707648
ORCID ID0000-0002-9560-4274
J-Global ID202001003241547790

Research Interests

 
分子イメージング ,放射性薬剤

Research Areas

 
  • Life sciences / Radiology / 放射性薬剤

Research History

 
Jan 2015
 - 
Today
Chiba University Graduate School of Pharmaceutical Sciences  
 
Apr 2013
 - 
Dec 2014
日本原子力研究開発機構 量子ビーム応用研究部門 博士研究員 
 

Education

 
Apr 2010
 - 
Mar 2013
Chiba University Graduate School of Medical and Pharmaceutical Sciences 
 
Apr 2008
 - 
Mar 2010
Chiba University Graduate School of Medical and Pharmaceutical Sciences 
 
Apr 2004
 - 
Mar 2008
Chiba University Faculty of Pharmaceutical Sciences 
 

Awards

 
Mar 2024
コニカミノルタ画像科学奨励賞
 
Mar 2022
日本薬学会 物理系薬学部会 奨励賞
 
Jun 2014
第15回放射線プロセスシンポジウム ポスターセッション優秀賞
 

Papers

12345>
 
 
Approaches to Reducing Normal Tissue Radiation from Radiolabeled Antibodies
Hiroyuki Suzuki   kento kannaka   Tomoya Uehara   
Pharmaceuticals      Apr 2024   [Refereed]
 
Resin-assisted synthesis of a neopentyl 211At-labeled activated ester possessing a triazole spacer and its application to the synthesis of in vivo stable 211At-labeled antibodies.
Masatoshi Tada   Yuta Kaizuka   Kento Kannaka   Hiroyuki Suzuki   Taiki Joho   Kazuhiro Takahashi   Tomoya Uehara   Hiroshi Tanaka   
   Apr 2024   
 
Neopentyl glycol-based radiohalogen-labeled amino acid derivatives for cancer radiotheranostics
Yuta Kaizuka   Hiroyuki Suzuki   Tadashi Watabe   Kazuhiro Ooe   Atsushi Toyoshima   Kazuhiro Takahashi   Koichi Sawada   Takashi Iimori   Yoshitada Masuda   Takashi Uno   Kento Kannaka   Tomoya Uehara   
EJNMMI Radiopharmacy and Chemistry   9(1)    Feb 2024   [Refereed]
Abstract

Background

L-type amino acid transporter 1 (LAT1) is overexpressed in various cancers; therefore, radiohalogen-labeled amino acid derivatives targeting LAT1 have emerged as promising candidates for cancer radiotheranostics. However, <...
 
Reduction of the Renal Radioactivity of 111In-DOTA-Labeled Antibody Fragments with a Linkage Cleaved by the Renal Brush Border Membrane Enzymes
Hiroyuki Suzuki   Mari Araki   Kouki Tatsugi   Kento Ichinohe   Tomoya Uehara   Yasushi Arano   
Journal of Medicinal Chemistry   66(13) 8600-8613   Jun 2023   [Refereed]
 
Delivery of aPD-L1 antibody to i.p. tumors via direct penetration by i.p. route: Beyond EPR effect
Mayu Yamamoto   Taiki Kurino   Reiko Matsuda   Haleigh Sakura Jones   Yoshito Nakamura   Taisei Kanamori   Atushi B. Tsuji   Aya Sugyo   Ryota Tsuda   Yui Matsumoto   Yu Sakurai   Hiroyuki Suzuki   Makoto Sano   Kensuke Osada   Tomoya Uehara   Yukimoto Ishii   Hidetaka Akita   Yasushi Arano   Akihiro Hisaka   Hiroto Hatakeyama   
Journal of Controlled Release   352 328-337   Dec 2022   [Refereed]

Professional Memberships

 
 
   
 
日本分子イメージング学会
 
   
 
日本核医学会
 
   
 
日本薬学会

Research Projects

12>
 
 
悪性黒色腫の標的α線治療を指向するAt-211標識薬剤開発
日本学術振興会: 科学研究費助成事業 基盤研究(C)
鈴木 博元 佐々木 一郎 大江 一弘 渡部 直史 
Project Year: Apr 2022 - Mar 2025
 
がんの標的アルファ線治療への応用を指向する生体内安定な211At標識法の開発
日本学術振興会: 二国間交流事業 フランス(MEAE-MESRI)との共同研究
Project Year: Apr 2023 - Mar 2025
 
悪性黒色腫に対する標的α線治療の実現性を向上するAt-211標識基盤技術の改良
日本学術振興会: 科学研究費助成事業
鈴木 博元 
Project Year: 2023 - 2023
 
Development of At-211-labeled agents targeting the tumor hypoxia region
Japan Society for the Promotion of Science: Grants-in-Aid for Scientific Research
Suzuki Hiroyuki 
Project Year: Apr 2019 - Mar 2022
 
Development of a versatile alpha particle therapy using At-211 labeled amino acids with controlled pharmacokinetics
Japan Society for the Promotion of Science: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)
HANAOKA Hirofumi 
Project Year: Apr 2018 - Mar 2021
Copyright (C) 2021 Chiba University All Rights Reserved.